Novo research director on obesity study: "We couldn't have hoped for a better start"
The first phase III study of Novo Nordisk's drug semaglutid in obesity exceeded the company's expectations and, according to research director Mads Krogsgaard Thomsen, proves that obesity is a chronic illness which needs to be treated like diabetes or high blood pressure.
BY KEVIN GRØNNEMANN, TRANSLATED BY CATHERINE BRETT
Log in to read our articles
Welcome to MedWatch. A part of our content is exclusive and reserved for our users.